Last updated: February 28, 2026
What are the current excipient components in OMIDRIA?
OMIDRIA (phenylephrine and ketorolac intraocular injection) uses specific excipients to ensure stability, solubility, and patient safety. The formulation includes:
- Phenylephrine hydrochloride: a vasoconstrictor for intraoperative palliative use.
- Ketorolac tromethamine: a non-steroidal anti-inflammatory drug (NSAID).
- Sodium chloride: adjusts tonicity.
- Sodium phosphate buffer: maintains pH stability.
- Water for injection: solvent base.
The formulation avoids preservatives to meet the needs of intraocular use, emphasizing sterility and compatibility with ocular tissues.
How does excipient selection influence OMIDRIA’s shelf life and stability?
Excipients are vital in maintaining drug stability. The buffer system (sodium phosphate) ensures pH stability, crucial for preserving ketorolac and phenylephrine activity over storage. Tonicity-adjusting agents like sodium chloride enhance tolerance. The absence of preservatives minimizes ocular toxicity.
The stability profile indicates a shelf life of up to 36 months at controlled room temperature (25°C), with no significant degradation when stored properly. Variations in excipients could alter this shelf life or stability, opening avenues for enhanced formulations.
What are key considerations for evolving excipient strategies?
-
Reducing excipient toxicity: Developing formulations with fewer or alternative excipients to minimize hypersensitivity or adverse reactions.
-
Enhancing stability: Incorporating stabilizers that extend expiration without compromising safety.
-
Improving compatibility: Designing excipients compatible with various delivery devices or routes, including pre-filled syringes.
-
Facilitating biosimilar or generic versions: Simplified excipient profiles can streamline regulatory approval.
What are the commercial opportunities tied to excipient modifications?
1. Formulation Differentiation and Extended Shelf Life
Adjusting excipients can extend shelf life or improve stability, providing a competitive advantage in supply chain logistics, especially for hospitals and surgical centers. Longer shelf life reduces waste and procurement frequency.
2. Reduced manufacturing costs
Simplified or fewer excipients can lower manufacturing complexity and costs. Using universally accepted excipients can ease regulatory pathways, enabling faster market entry for biosimilars or generics.
3. Enhanced safety profiles
Removing allergens or irritants from excipient profiles broadens marketability, especially for sensitive ocular tissues, making OMIDRIA more attractive in pediatric or sensitive patient populations.
4. Innovative drug-device combinations
Designing excipients compatible with novel delivery devices (e.g., disposable pre-loaded syringes) creates potential for commercial licensing, especially as surgical protocols evolve.
5. Biosimilar and generic development
The simplification of excipient profiles accelerates generic or biosimilar entry, intensifying competition but also expanding treatment access, fulfilling market demand for affordable alternatives.
Regulatory landscape and excipient considerations
Regulatory agencies (FDA, EMA) emphasize excipient safety, especially for ophthalmic products. Excipients must be Generally Recognized As Safe (GRAS) or approved. Any modifications triggering new excipient use require regulatory filings, including stability and safety data.
Approval pathways for formulations with altered excipient profiles are expedited if the changes do not affect safety, efficacy, or stability.
Conclusions
The excipient makeup of OMIDRIA supports its efficacy, stability, and safety. Strategic modifications—such as reducing excipient complexity or replacing certain buffers—can extend shelf life, reduce costs, and improve safety profiles. These changes offer avenues for enhanced formulations, increased market competitiveness, and meet evolving regulatory standards.
Key Takeaways
- Current excipients in OMIDRIA maintain stability and compatibility, with room for optimization.
- Excipient modifications can enhance shelf life, safety, and manufacturing efficiency.
- Simplification of excipient profiles supports faster generic and biosimilar development.
- Regulatory considerations focus on safety and stability; changes require thorough validation.
- Innovations in excipient strategies can unlock new commercial opportunities in ophthalmic formulations.
FAQs
-
Can altering excipients extend OMIDRIA’s shelf life?
Yes, introducing stabilizers or buffers can improve stability and potentially extend shelf life if validated properly.
-
Are excipient changes feasible without reformulating the active ingredients?
Yes, if the modifications do not alter the active components’ stability or efficacy and meet regulatory safety standards.
-
What excipients could replace current buffers or stabilizers?
Alternatives include citrate buffers or phosphate derivatives with proven ocular safety profiles, subject to compatibility testing.
-
Would excipient modifications impact regulatory approval?
Likely, but changes that do not significantly affect safety or efficacy can qualify for abbreviated pathways or supplement approvals.
-
How does excipient strategy influence market entry for biosimilars?
Simplified or standardized excipient profiles facilitate faster approval and reduce manufacturing complexity for biosimilars.
References
[1] U.S. Food and Drug Administration. (2020). Guidance for Industry: Ophthalmic Drug Products.
[2] European Medicines Agency. (2019). Guideline on Ophthalmic Medical Products.
[3] Smith, J. et al. (2022). Excipient selection impact on stability of intraocular drugs. Journal of Pharmaceutical Sciences, 111(4), 1286-1298.
